25, 2015 /PRNewswire/ -- Neurocrine
We are interested in securing commercial rights to NBI-6024 especially in the United States and are now able to move forward with this plan," said Gary Lyons, President and CEO of Neurocrine
Gary Lyons, president and CEO of Neurocrine
will present results from the ongoing Insomnia Clinical Trials that have been completed to date as well as an update of the company's other clinical development and research programs.
With the initiation of this trial, Neurocrine
now has five clinical development programs including insomnia, malignant glioma, diabetes and multiple sclerosis with two additional compounds planned to enter new Phase I studies in 2001.
In July 2000, Neurocrine
licensed to Taisho the exclusive rights to develop and commercialize NBI-6024 in Europe and Asia.
Fifteen independent studies relating to CRF were presented including research efforts from within Neurocrine
as well as its collaborators from Emory University, University of Wisconsin, and the Max Planck Institute for Psychiatry, Munich and the University of California, Irvine.
In the news release, Neurocrine
Biosciences to Present at the Morgan Stanley Global Healthcare Conference, issued 10-Sep-2015 by Neurocrine
Biosciences reported that an Investigational New Drug application (IND) was submitted to the Food & Drug Administration (FDA) and approved to initiate a Phase I/II clinical study in the U.
The current publication compares the Phase II clinical trial to a pilot study with NBI 5788 conducted at the National Institutes of Health (NIH) and sponsored by Neurocrine
Biosciences under a Cooperative Research and Development Agreement (CRADA).
para]]SAN DIEGO, June 2, 2015 /PRNewswire/ -- Neurocrine
We are encouraged by our findings of the underlying etiology of narcolepsy and look forward to working with Neurocrine
Biosciences to develop therapeutics for this devastating disease" said Emmanuel Mignot, M.
SAN DIEGO, May 27, 2015 /PRNewswire/ -- Neurocrine